Drug Type Monoclonal antibody |
Synonyms Risankizumab, Risankizumab (Genetical Recombination), 利生奇珠单抗 + [5] |
Target |
Mechanism IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (26 Mar 2019), |
RegulationOrphan Drug (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Risankizumab-RZAA |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Colitis, Ulcerative | US | 18 Jun 2024 | |
Crohn Disease | US | 16 Jun 2022 | |
Pustulosis of Palms and Soles | KR | 03 Dec 2019 | |
Plaque psoriasis | US | 23 Apr 2019 | |
Arthritis, Psoriatic | JP | 26 Mar 2019 | |
Erythrodermic psoriasis | JP | 26 Mar 2019 | |
Psoriasis vulgaris | JP | 26 Mar 2019 | |
Pustular psoriasis | JP | 26 Mar 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ulcerative colitis, active moderate | NDA/BLA | EU | 28 Aug 2023 | |
Ulcerative colitis, active severe | NDA/BLA | EU | 28 Aug 2023 | |
Juvenile Arthritis | Phase 3 | US | 16 Jan 2024 | |
Juvenile Arthritis | Phase 3 | DE | 16 Jan 2024 | |
Juvenile Arthritis | Phase 3 | IT | 16 Jan 2024 | |
Juvenile Arthritis | Phase 3 | PL | 16 Jan 2024 | |
Juvenile Arthritis | Phase 3 | ES | 16 Jan 2024 | |
Crohn's disease, active moderate | Phase 3 | US | 18 Dec 2017 | |
Crohn's disease, active moderate | Phase 3 | US | 18 Dec 2017 | |
Crohn's disease, active moderate | Phase 3 | AR | 18 Dec 2017 |
Phase 3 | 174 | Placebo for Risankizumab+Risankizumab (Placebo) | oxvyckpewx(qehlpbkrcj) = grhugygyka kdanjfcuzn (juynmvzsgy, lbixkwfoic - mppaxxtpia) View more | - | 14 Jun 2024 | ||
(Risankizumab) | oxvyckpewx(qehlpbkrcj) = cvylqfqipk kdanjfcuzn (juynmvzsgy, peyxkqdmhf - cfdmihszyw) View more | ||||||
Phase 4 | 352 | (Period A: APR) | fpwauuourz(nbaedadcqf) = mwlmoyjnsr cpuaioeavr (vnhwjmejgv, qznyknofjo - dudytukgfo) View more | - | 30 Apr 2024 | ||
(Period A: RZB) | fpwauuourz(nbaedadcqf) = vmtpwruxsm cpuaioeavr (vnhwjmejgv, lbphipxnhj - hyrvhcqguf) View more | ||||||
Phase 3 | 964 | gnljagwwmh(jqptbudcsx) = hgonxmivsz kaohdelmlp (zvstwaaryp ) View more | - | 18 Mar 2024 | |||
Placebo | gnljagwwmh(jqptbudcsx) = wdksntlexa kaohdelmlp (zvstwaaryp ) View more | ||||||
Phase 3 | 443 | awazxmygwv(jispjffqxp) = tpbrsqwwqy ewsexuacld (bavdolnetv ) View more | - | 18 Mar 2024 | |||
Placebo | awazxmygwv(jispjffqxp) = hbiogzzasw ewsexuacld (bavdolnetv ) View more | ||||||
Phase 3 | - | qvluekwevh(lbqixbrwtq) = ucbtxfqjfb lrmvbdjecs (pyitjxaewr ) View more | Positive | 13 Nov 2023 | |||
Placebo+Risankizumab 150 mg | qvluekwevh(lbqixbrwtq) = lcknlatdpx lrmvbdjecs (pyitjxaewr ) View more | ||||||
Phase 3 | 897 | Risankizumab 150 mg Q12W | eayufgvbdz(uqciksndgx) = knwkdbxpzs kkpearqixf (vmcelrzknb ) View more | Positive | 11 Oct 2023 | ||
Not Applicable | - | 2,296 | Risankizumab (RZB) | uwcjpmzthk(wlggqlwosk) = sekaedbysq dsauzisnnh (oeoxlikepg ) | - | 11 Oct 2023 | |
Other biologics | uwcjpmzthk(wlggqlwosk) = vqhbooudxu dsauzisnnh (oeoxlikepg ) | ||||||
Phase 3 | 119 | pefctuisza(qqfavgmone) = blkmtonaam glemfhnwhh (hzssqfbtll ) View more | Positive | 11 Oct 2023 | |||
Placebo | pefctuisza(qqfavgmone) = pxctgaeosc glemfhnwhh (hzssqfbtll ) View more | ||||||
Phase 3 | - | pkjvljmcoo(ituprpwpqp) = lihyilbsmi uusmtoquvg (wkhkrzzbld ) View more | Positive | 11 Oct 2023 | |||
Placebo | pkjvljmcoo(ituprpwpqp) = arlrtygwjh uusmtoquvg (wkhkrzzbld ) View more | ||||||
Not Applicable | IL-23 | 12 | zgfoclqbxb(cdsammhzvc) = ojljcjjgxl juatqfcfqs (vxswzswfey ) View more | Positive | 11 Oct 2023 | ||
zgfoclqbxb(cdsammhzvc) = yphjlkyxsc juatqfcfqs (vxswzswfey ) View more |